Abstract
Remarkable successes with the FDA-approved proteasome inhibitors bortezomib (Velcade®) and carfilzomib (Kyprolis®) have proved that the proteasome is an effective target for the treatment of multiple myeloma. In other hematological malignancies, however, clinical trials of proteasome-targeting drugs have shown generally disappointing results to date. Additionally, existing proteasome inhibitors have significant issues with toxicity, poor response rate, and the emergence of resistance for many patients. A new generation of small-molecule therapies specifically targeting the immunoproteasome may have the potential to overcome the drawbacks of bortezomib and carfilzomib in multiple myeloma and to bring significant benefits of proteasome inhibitor therapies to many more patients. In this article, we describe the potential of the immunoproteasome as a therapeutic target for hematological malignancies and the recent progress in the development of useful immunoproteasome inhibitors.
Keywords: Constitutive proteasome, immunoproteasome, mantle cell lymphoma, multiple myeloma, small molecule inhibitors, subunit-selective inhibitor.
Current Cancer Drug Targets
Title:The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Volume: 14 Issue: 6
Author(s): Zachary Miller, Wooin Lee and Kyung Bo Kim
Affiliation:
Keywords: Constitutive proteasome, immunoproteasome, mantle cell lymphoma, multiple myeloma, small molecule inhibitors, subunit-selective inhibitor.
Abstract: Remarkable successes with the FDA-approved proteasome inhibitors bortezomib (Velcade®) and carfilzomib (Kyprolis®) have proved that the proteasome is an effective target for the treatment of multiple myeloma. In other hematological malignancies, however, clinical trials of proteasome-targeting drugs have shown generally disappointing results to date. Additionally, existing proteasome inhibitors have significant issues with toxicity, poor response rate, and the emergence of resistance for many patients. A new generation of small-molecule therapies specifically targeting the immunoproteasome may have the potential to overcome the drawbacks of bortezomib and carfilzomib in multiple myeloma and to bring significant benefits of proteasome inhibitor therapies to many more patients. In this article, we describe the potential of the immunoproteasome as a therapeutic target for hematological malignancies and the recent progress in the development of useful immunoproteasome inhibitors.
Export Options
About this article
Cite this article as:
Miller Zachary, Lee Wooin and Kim Bo Kyung, The Immunoproteasome as a Therapeutic Target for Hematological Malignancies, Current Cancer Drug Targets 2014; 14 (6) . https://dx.doi.org/10.2174/1568009614666140723113139
DOI https://dx.doi.org/10.2174/1568009614666140723113139 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency
Current Gene Therapy The Price of the Successful Treatment of Pediatric Malignancies
Current Pediatric Reviews Review of Chemoradiotherapy for High-Risk Prostate Cancer
Reviews on Recent Clinical Trials Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Current Drug Targets Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry Update on MDS Therapy: From Famine to Feast
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?
Current Drug Safety Modulation of Mast Cell and Basophil Functions by Benzene Metabolites
Current Pharmaceutical Design Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Current Drug Delivery